MedTrace Logo

The Role of Luteolin Supplementation in Cellular Metabolism of Myocytes and Fat Cells, Physical Performance, and Body Composition in Athletes.

NCT07280520 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-12-12

No results posted yet for this study

Summary

A clinical trial is to determine whether Luteolin supplementation can enhance cellular metabolism and improve physical performance in apparently healthy Jordanian male athletes aged 18-35 with continuous training experience.

The main questions it aims to answer are:

* Does 12 weeks of Luteolin supplementation increase the gene expression of MEF2 (a factor promoting muscle development and endurance)?
* Does 12 weeks of Luteolin supplementation decrease the gene expression of SREBP-1 (a factor regulating fat storage)?
* Does Luteolin supplementation lead to improvements in key performance metrics, such as maximal oxygen consumption VO2 max) and anaerobic power?
* Does Luteolin supplementation positively impact body composition, specifically by reducing fat mass and increasing lean muscle mass? Researchers will compare the group receiving the active Luteolin supplement (100 mg daily) to a placebo group receiving a microcrystalline cellulose supplement (a neutral substance) to determine whether the active supplement has the desired effects on metabolism, performance, and body composition.

Participants will:

* Take one capsule (either Luteolin or placebo) daily for 12 weeks.
* Continue their usual diet and exercise regimen but restrict intake of high-Luteolin foods during the study period.
* Provide a blood sample for gene expression analysis before and after the 12-week intervention.
* Undergo performance assessments, VO2 max and Wingate test, and body composition analysis (BIA) before and after the 12-week intervention.

Conditions

  • Healthy Athletes

Interventions

DIETARY_SUPPLEMENT

luteolin

100 mg Luteolin (Active Ingredient), taken orally once daily for 12 weeks.

OTHER

Placebo

Microcrystalline cellulose (Placebo), taken orally once daily for 12 weeks. The capsule is matched in size, color, and taste to the active Luteolin supplement.

Sponsors & Collaborators

  • University of Jordan

    lead OTHER

Principal Investigators

  • Hadeel A Ghazzawi, professor · The University of Jordan School of Agriculture

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2025-12-31
Completion
2026-02-28

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07280520 on ClinicalTrials.gov